Cell Signaling Technology Expands Partnership with Bio-Rad to Develop Phosphoprotein Assays for Kinase and Signal Transduction Research and Drug Discovery.DANVERS, Mass. -- Cell Signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as Technology, Inc. (CST CST abbr. 1. Central Standard Time 2. convulsive shock treatment CST Central Standard Time Noun 1. ), announced today that it has entered into a new partnership agreement with Bio-Rad Laboratories, Inc. (AMEX AMEX See: American Stock Exchange : BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics. Under the new agreement, CST will develop antibodies for kinase activation and protein phosphorylation phosphorylation, chemical process in which a phosphate group is added to an organic molecule. In living cells phosphorylation is associated with respiration, which takes place in the cell's mitochondria, and photosynthesis, which takes place in the chloroplasts. assays that will be commercialized in Bio-Rad's multiplex bead-based assays for the Bio-Plex(R) suspension array system. CST's scientific and technical expertise will be leveraged to develop a broader array of antibodies for Bio-Rad's Bio-Plex(R) platform, enabling multiplexed measurement of phosphoproteins and signaling pathways. Bio-Plex(R) phosphoprotein phosphoprotein /phos·pho·pro·tein/ (-pro´ten) a conjugated protein in which phosphoric acid is esterified with a hydroxy amino acid. phos·pho·pro·tein n. assays are optimized for simultaneous assessment of kinase and signaling protein activation states and provide critical tools for disease research and drug development. Given the complexity of cellular signaling and the diversity of mechanistic abnormalities underlying disease, Bio-Plex(R) multiplexed phosphoprotein assays can facilitate the understanding of disease and the development of more effective targeted therapeutic strategies. "Our partnership with Bio-Rad in the past has enabled CST to combine our antibody expertise with Bio-Rad's strength in multiplexed assay technologies," said Christopher Bunker, CST's Director of Business Development. "Bio-Plex phosphoprotein assays built with CST antibody content provide the means for rigorous parallel analysis of signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. pathways." "Advances in cellular signaling research will have a great impact both in our understanding of fundamental biological processes and in advancing the treatment of disease," said Bio-Rad Vice President and Group Manager, Life Science Group, Brad Crutchfield. "Together, CST and Bio-Rad can provide more quickly a broader array of tools for kinase and signal transduction research." About Cell Signaling Technology Cell Signaling Technology, Inc., has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST's phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in basic scientific and drug discovery research. Information on CST can be obtained at the Company's website at www.cellsignal.com About Bio-Rad Bio-Rad Laboratories, Inc. (www.bio-rad.com), is a multinational manufacturer and distributor of life science research products and clinical diagnostics. Based in Hercules, California, Bio-Rad serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. offices. Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion